Insulin is a peptide hormone secreted by the beta cells of the pancreatic islets. Insulin allows the human body to utilize sugar from the carbohydrates in the food for energy or for storing glucose for future utilization. It has a significant impact on the metabolism of fats, proteins, and carbohydrates and promotes the absorption of glucose from the blood into the liver and skeletal muscles. Insulin also aids in keeping the blood sugar level from getting too low (hypoglycemia) or too high (hyperglycemia). When the pancreas are not able to produce the required amount of insulin or any insulin at all, the amount of glucose rises in the blood and results in the condition of diabetes.

Obtain the Sample Containing the Future Market Perspectives of Insulin Industry In China and Worldwide at: http://bit.ly/2jTeT53

As per the WHO, in 2011, over 366 mn individuals globally were diagnosed with diabetes and it is predicted that an additional 280 mn individuals will be diagnosed with diabetes in the coming 20 years. According to the report, the rising diabetic population and the increasing entry barriers for biosimilar manufacturers are amongst the major factors boosting the growth of the global and China insulin market. In addition, the relative absence of stringent regulations on price capping is another factor having a positive impact on the growth of the market. A strong pipeline of products and the proliferation of combination products are the key opportunities seen in this market.

On the other hand, the increasing inclination toward SGLT2 and GLP-1 agents amongst the patients having diabetes 2 will impede the use of insulin therapy, thus hampering the growth of the global and China insulin market. In addition, the soaring costs of products may also inhibit the demand for insulin especially in the developing nations, hence impacting the market negatively.

On the basis of mode of action, the report segments the global and China insulin market into short-acting, rapid-acting, premixed, intermediate-acting, and long-acting insulin. Amongst these, the segment of long-acting insulin is predicted to be the most swiftly developing segment in the global and China insulin market in the forecast horizon. This segment will rise at an 8.70% CAGR from 2013 to 2019. This is owing to the increasing benefits of long-acting insulin derivatives such as lower count of doses in comparison to other derivatives. On the other hand, in China, premixed insulin derivatives constituted a share of over 50% in the market in 2012. This is owing to the increasing population having type 1 diabetes, the improvement in the medical infrastructure, and the soaring consumption of fast food within China. By source, the market is segmented into modern insulin and human insulin.

Read the Current Trends of Global and China Insulin Market at: http://www.transparencymarketresearch.com/insulin-market.html

Geographically, the report segments the market into Europe, Asia Pacific, North America, and Rest of the World (RoW). Sanofi, Eli Lilly and Company, and Novo Nordisk A/S are the key players dominant in the market. These players constitute a share of over 80% in the insulin market within China. On the other hand, Tonghua Dongbao and Shanghai Fosun Pharmaceutical Co., Ltd. are some of the domestic players holding a small share in the China insulin market.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com/